Mironid, a University of Glasgow spin-off, closed a €39.9 million Series B financing on 5 August 2026. The round was led by the Scottish National Investment Bank with participation from Roche Venture Fund and Epidarex Capital.
Mironid announced the completion of a €39.9 million ($46 million) Series B funding round on 5 August 2026, a development reported by industry outlets on 7 and 8 August 2026 [1][2]. The biopharmaceutical company is headquartered in Glasgow, United Kingdom, and originated as a spin-off from the University of Glasgow’s research programme [1]. The financing is intended to support the pre-clinical and clinical development of a therapeutic candidate for autosomal dominant polycystic kidney disease (ADPKD), a rare and progressive kidney disorder [2].
The lead investor in the round was the Scottish National Investment Bank, which contributed a significant portion of the capital [2]. Additional investors included Roche Venture Fund and Epidarex Capital, both of which participated alongside the lead investor [2]. The Series B round follows Mironid’s earlier seed and Series A financings that established the company’s platform for targeting rare kidney diseases [3].
Funding Structure and Investor Participation
The €39.9 million Series B round was structured as an equity financing, with the Scottish National Investment Bank acting as the lead syndicate manager [2]. Roche Venture Fund contributed a minority stake, leveraging its global experience in biotech investments to support Mironid’s therapeutic pipeline [2]. Epidarex Capital, a UK-focused venture firm, also took part in the round, adding strategic expertise in life-science commercialization [2]. The round was closed on 5 August 2026 after a due-diligence process that evaluated Mironid’s pre-clinical data, intellectual property portfolio, and regulatory strategy [1][3].
Mironid’s capital raise brings its total funding to approximately €70 million since its founding in 2015 [3]. The Series B proceeds are earmarked for advancing the ADPKD drug candidate through IND-enabling studies, expanding manufacturing capabilities, and initiating Phase I clinical trials in the United Kingdom and Europe [2][3]. The company also plans to allocate resources toward recruiting additional scientific and regulatory personnel to accelerate the development timeline [3].
The company also plans to allocate resources toward recruiting additional scientific and regulatory personnel to accelerate the development timeline [3].
Development Plan for ADPKD Therapy
Glasgow-Based Mironid Secures €39.9 Million Series B to Advance Rare Kidney Disease Therapy
Mironid’s therapeutic program targets the molecular pathways that drive cyst formation in ADPKD, a disease affecting an estimated 12 million people worldwide [2]. The Series B funding will finance pre-clinical toxicology studies required for an Investigational New Drug (IND) application with the UK Medicines and Healthcare products Regulatory Agency (MHRA) [2][3]. Upon IND clearance, Mironid intends to commence a Phase I safety trial in healthy volunteers, followed by a Phase II efficacy study in patients with early-stage ADPKD [2].
Six students in Ranchi maintain a 16-day hunger strike demanding a CBI probe into alleged recruitment exam leaks, while the state prepares for a student…
The company’s research platform leverages proprietary small-molecule inhibitors identified through high-throughput screening at the University of Glasgow’s biomedical research facilities [1]. Intellectual property protection for the lead compound has been secured through patents filed in the United Kingdom, the European Union, and the United States [4]. The infusion of Series B capital is expected to reduce the projected development timeline by up to twelve months, according to the company’s internal milestones [3].
Impact on Education and Healthcare Stakeholders
The infusion of €39.9 million into Mironid’s pipeline creates immediate opportunities for students and researchers in biomedical science programmes at the University of Glasgow and other UK institutions [2]. Laboratory collaborations and internship placements are expected to expand as the company scales its research and development activities [2]. For educators, the funding underscores the viability of university spin-offs as pathways for translating academic research into commercial therapeutics [4].
Healthcare providers may anticipate earlier access to a targeted ADPKD treatment pending successful clinical outcomes [2]. The funding also contributes to the broader UK biotechnology sector, supporting job creation in high-skill roles and reinforcing Glasgow’s position as a hub for life-science innovation [4]. Patients with ADPKD and advocacy groups are likely to monitor Mironid’s progress closely, given the unmet medical need for disease-modifying therapies [2].
Key Facts
What: Mironid closed a €39.9 million Series B financing to develop a rare kidney disease treatment.
Healthcare providers may anticipate earlier access to a targeted ADPKD treatment pending successful clinical outcomes [2].
When: Funding round closed on 5 August 2026; reported on 7-8 August 2026.
Impact: Accelerates ADPKD drug development, creates research opportunities, and supports UK biotech growth.
Westpac economist Illiana Jain predicts the Federal Reserve will maintain interest rates, prompting analysts to reassess their economic models and strategies.
NewsNews
